Vitae Biomedical Co., Ltd. has secured a patent in Australia for its core lung cancer detection technology, marking a key milestone in the transition from patent filings to granted intellectual property rights.

This approval further strengthens the company’s global IP strategy, reinforcing protection across major markets and supporting its competitive position in non-invasive cancer diagnostics. The addition of Australia enhances coverage in the Asia-Pacific region and English-speaking markets, contributing to a more comprehensive and enforceable IP framework.

With this latest grant, Vitae Biomedical continues to build an interconnected patent portfolio spanning the United States, Japan, Taiwan, Australia, and other key regions. This structured approach not only strengthens technological protection but also lays the foundation for future licensing opportunities and cross-border strategic partnerships.

Looking ahead, the company will continue translating its research and development achievements into real-world applications, balancing commercial expansion with its mission to improve accessibility in early disease detection. Through its growing IP portfolio, Vitae Biomedical aims to deliver long-term value in global precision healthcare.